AbL Diagnostics SA (ABLD) - Total Assets
Based on the latest financial reports, AbL Diagnostics SA (ABLD) holds total assets worth €11.10 Million EUR (≈ $12.98 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ABLD net asset value for net asset value and shareholders' equity analysis.
AbL Diagnostics SA - Total Assets Trend (2007–2024)
This chart illustrates how AbL Diagnostics SA's total assets have evolved over time, based on quarterly financial data.
AbL Diagnostics SA - Asset Composition Analysis
Current Asset Composition (December 2024)
AbL Diagnostics SA's total assets of €11.10 Million consist of 71.4% current assets and 28.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €60.54K | 4.0% |
| Accounts Receivable | €3.23 Million | 27.4% |
| Inventory | €699.41K | 5.9% |
| Property, Plant & Equipment | €463.38K | 3.9% |
| Intangible Assets | €2.71 Million | 22.9% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how AbL Diagnostics SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ABLD company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AbL Diagnostics SA's current assets represent 71.4% of total assets in 2024, a decrease from 96.3% in 2007.
- Cash Position: Cash and equivalents constituted 4.0% of total assets in 2024, up from 3.9% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 27.4% of total assets.
AbL Diagnostics SA Competitors by Total Assets
Key competitors of AbL Diagnostics SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
VSee Health, Inc.
NASDAQ:VSEE
|
USA | $18.71 Million |
|
Oakridge International Ltd
AU:OAK
|
Australia | AU$1.61 Million |
|
Pro Medicus Ltd
AU:PME
|
Australia | AU$533.91 Million |
|
Echoiq Ltd
AU:EIQ
|
Australia | AU$17.99 Million |
|
ARTRYA Ltd
AU:AYA
|
Australia | AU$23.68 Million |
|
Cogstate Ltd
AU:CGS
|
Australia | AU$64.77 Million |
|
Alcidion Group Ltd
AU:ALC
|
Australia | AU$115.63 Million |
|
Oneview Healthcare Plc
AU:ONE
|
Australia | AU$15.49 Million |
AbL Diagnostics SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.26 | 2.06 | 211.81 |
| Quick Ratio | 2.91 | 1.92 | 211.81 |
| Cash Ratio | 0.00 | 0.00 | 208.31 |
| Working Capital | €5.35 Million | €5.26 Million | €7.15 Million |
AbL Diagnostics SA - Advanced Valuation Insights
This section examines the relationship between AbL Diagnostics SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.59 |
| Latest Market Cap to Assets Ratio | 3.59 |
| Asset Growth Rate (YoY) | -20.8% |
| Total Assets | €11.81 Million |
| Market Capitalization | $42.45 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values AbL Diagnostics SA's assets at a significant premium (3.59x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: AbL Diagnostics SA's assets decreased by 20.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for AbL Diagnostics SA (2007–2024)
The table below shows the annual total assets of AbL Diagnostics SA from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €11.81 Million ≈ $13.81 Million |
-20.76% |
| 2023-12-31 | €14.90 Million ≈ $17.42 Million |
-3.28% |
| 2022-12-31 | €15.41 Million ≈ $18.01 Million |
+467.87% |
| 2021-12-31 | €2.71 Million ≈ $3.17 Million |
+14.04% |
| 2020-12-31 | €2.38 Million ≈ $2.78 Million |
-66.99% |
| 2019-12-31 | €7.21 Million ≈ $8.43 Million |
-6.95% |
| 2018-12-31 | €7.75 Million ≈ $9.06 Million |
+3.21% |
| 2017-12-31 | €7.51 Million ≈ $8.78 Million |
+8.51% |
| 2016-12-31 | €6.92 Million ≈ $8.09 Million |
-6.77% |
| 2015-12-31 | €7.42 Million ≈ $8.67 Million |
+12.97% |
| 2014-12-31 | €6.57 Million ≈ $7.68 Million |
+11.20% |
| 2013-12-31 | €5.91 Million ≈ $6.90 Million |
+11.54% |
| 2012-12-31 | €5.29 Million ≈ $6.19 Million |
+1.66% |
| 2011-12-31 | €5.21 Million ≈ $6.09 Million |
+0.86% |
| 2010-12-31 | €5.16 Million ≈ $6.04 Million |
+1.68% |
| 2009-12-31 | €5.08 Million ≈ $5.94 Million |
+1.18% |
| 2008-12-31 | €5.02 Million ≈ $5.87 Million |
+2.53% |
| 2007-12-31 | €4.90 Million ≈ $5.72 Million |
-- |
About AbL Diagnostics SA
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more